Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)Birgit Schoeberl(Merrimack Pharmaceuticals (United States)), Gavin MacBeath(Harvard University)npj Systems Biology and ApplicationsJanuary 5, 201710.1038/npjsba.2016.34Cited by 76SaveCiteExport RISWatch citationsRelated PapersHigh- and Low-Affinity Epidermal Growth Factor Receptor-Ligand Interactions Activate Distinct Signaling Pathways|PLoS ONE|2011|103A System-Wide Investigation of the Dynamics of Wnt Signaling Reveals Novel Phases of Transcriptional Regulation|PLoS ONE|2010|54